0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial

• DOI: 10.18240/ijo.2023.06.17
• Publication Date: 2023-05-30T07:39:11Z
• Authors: Qin Zhu; ; Zhi-Juan Hua; Li-Ping Xue; Yuan Zhou; Jie-Ying Zhang; Ying-Ting Zhu; Xiao-Fan Zhang
• Keywords: Placebo group

To evaluate the effect of 0.05% atropine on control myopia for 2y (phase I) and spherical equivalent refraction (SER) progression 1y II) after its withdrawal in Chinese myopic children.Totally 142 children with were randomly assigned to group or placebo group. In phase I, received 1 treatment each eye daily. II, patients no treatment. Axial length (AL), SER, intraocular pressure (IOP) atropine-related side effects assessed at 6 months' intervals.During mean change SER was -0.46±0.30 D group, compared -1.72±1.12 (P<0.001). The AL (0.26±0.30 mm) significantly shorter than that (0.76±0.62 mm, P=0.002). addition, II (12mo atropine), there significant difference from when (0.31±0.25 mm vs 0.28±0.26 P>0.05). Furthermore, 0.50±0.41 D, which lower 0.72±0.60 (P<0.05). Finally, statistically differences IOP between groups any stages (all P>0.05).The use two consecutive years may effectively elongation thus myopia, without withdrawal. Therefore, daily is effective safe.